Mixed Phenotype Acute Leukemia — Trials

Mixed Phenotype Acute Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

96 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 29
Ph III recruiting: 2
Growth YoY: —
Industry share: 17%
Top sponsor: Fred Hutchinson Cancer Center
Termination share: 41.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03959085	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy	recruiting	Phase 3	5,951	Children's Oncology GroupNETWORK	5	Aug 25, 2026	clinicaltrials
NCT05327894	Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia(Interfant-21)	recruiting	Phase 3	160	Princess Maxima Center for Pediatric OncologyOTHER	24